OssDsign Receives Innovative Technology Contract from Vizient for OssDsign Cranial PSI
Uppsala, Sweden December 16, 2021– OssDsign AB (publ) announced its patient-specific cranial implant OssDsign Cranial PSI has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the US. The contract was awarded based on the recommendation of OssDsign Cranial PSI by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the health care industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.
OssDsign Cranial PSI is a patient-specific cranial implant designed for the reconstruction of cranial defects, an area of treatment where post-operative infections have been shown to be a common form of complication. The implant is made from 3D printed medical-grade titanium covered by a calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient's own bone. Over time, the osteoconductive ceramic component degrades and is replaced with bone, leaving the patient with a well-integrated implant, potentially lasting a lifetime.
“The fact that OssDsign Cranial PSI has been awarded an Innovative Technology contract is a clear and strong testimony to the high level of innovation presented in our bone replacement technology, which has, time and again, proven to result in lower observed rates of complications in patients undergoing cranial surgeries. We look forward to offering members of Vizient’s substantial network our products and expertise to ensure better clinical outcomes in patients,” says Morten Henneveld, CEO, OssDsign.
“Health care experts on Vizient member councils evaluated OssDsign Cranial PSI as part of our Innovative Technology Program,” said Debbie Archer, director of procurement and Vizient Innovative Technology Program leader. “The council agreed to the contract, which indicates OssDsign Cranial PSI has one or more qualities that differentiates it from similar products and has potential to make an incremental improvement in health care. Congratulations to OssDsign AB.”
Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $110 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to health care. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: